Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.91 USD | +1.67% | -1.37% | -20.42% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-20.42% | 931M | C+ | ||
+12.07% | 3,131B | C+ | ||
+11.35% | 87.46B | B | ||
+14.31% | 84.87B | B+ | ||
-6.76% | 58.67B | B+ | ||
+42.75% | 54.23B | D+ | ||
-18.80% | 50.1B | B- | ||
+21.19% | 42.64B | D+ | ||
+32.27% | 30.36B | D+ | ||
-8.72% | 25.06B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Definitive Healthcare Corp. - Nasdaq
- Ratings Definitive Healthcare Corp.